Embolism: Clinical Trials

13 trials for Embolism, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 terminated. 13 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 313Terminated 13
Phase 22Terminated 2

Follow Embolism: new trials by email Literature Review of Embolism trials Research Report on Embolism

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
Abelacimab, Dalteparin - Venous Thromboembolism, Deep Venous Thrombosis
Phase 3TerminatedAnthos Therapeutics, Inc.4172022-09-272026-04-17
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
Abelacimab, Apixaban - Venous Thromboembolism, Deep Venous Thrombosis
Phase 3TerminatedAnthos Therapeutics, Inc.11502022-05-052026-02-23
Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19
Enoxaparin 40Mg/0.4Ml Inj Syringe 0.4Ml - COVID-19, Pulmonary Embolism, Deep Vein Thrombosis
Phase 3TerminatedUniversity of Zurich4752020-06-152022-05-25
Catheter-Directed Thrombolysis Versus Anticoagulation Monotherapy in Intermediate-High Risk PE
Conventional catheter-directed thrombolysis (CDT) with recombinant tissue plasminogen activator (rtPA), Enoxaparin - Pulmonary Embolism, Pulmonary Thromboembolisms
Phase 3TerminatedRajaie Cardiovascular Medical and Research Center942018-12-222021-12-29
Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants
Apixaban, Rivaroxaban, Heparin - Renal Insufficiency
Phase 3TerminatedCentre Hospitalier Universitaire de Saint Etienne2032016-10-192022-10-19
Compare Technegas Ventilation-Perfusion SPECT and Xenon Ventilation-Perfusion Planar Imaging for Pulmonary Embolism
Technegas V SPECT imaging, Xenon-133 Ventilation Planar imaging - Pulmonary Embolism
Phase 3TerminatedCyclomedica Australia PTY Limited182012-08-012015-11-10
Diclofenac for Submassive PE
Diclofenac, Placebo - Pulmonary Embolism
Phase 2 / Phase 3TerminatedMinistry of Health, Spain342012-05-012017-09-06
A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients
dalteparin injection - Venous Thromboembolism, Pulmonary Embolism
Phase 3TerminatedUniversity of Rochester2182009-07-012015-11-24
Clot Dissolving Treatment for Blood Clots in the Lungs
Tenecteplase + Enoxaparin, 0.9% Saline + Enoxaparin - Pulmonary Embolism
Phase 3TerminatedWake Forest University Health Sciences832008-05-012022-10-12
Carbon Dioxide Insufflation on Cerebral Microemboli
Carbon dioxide insufflation - Cardiovascular Disease, Mitral Valve Repair
Phase 2 / Phase 3TerminatedUniversity Health Network, Toronto202008-04-012011-10-26
Study of Alfimeprase's Ability to Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery
alfimeprase - Arterial Occlusive Diseases
Phase 3TerminatedARCA Biopharma, Inc.3002006-04-012008-01-15
D-Dimer and IPG for Recurrent Thrombosis (DIRECT)
venogram - Deep Vein Thrombosis, Pulmonary Embolism
Phase 3TerminatedHamilton Health Sciences Corporation6001998-12-012005-09-16
Canadian Pulmonary Embolism Diagnosis Study (CANPEDS)
Two diagnostic management strategies - Suspected Pulmonary Embolism, Deep Venous Thrombosis
Phase 3TerminatedHamilton Health Sciences Corporation11261998-08-012006-05-03

Narrower conditions

Pulmonary Embolism (11)  ·  Venous Thrombosis (6)  ·  Venous Thromboembolism (5)  ·  Thrombosis (3)  ·  Ventricular Dysfunction, Right (2)  ·  Arterial Occlusive Diseases (1)  ·  COVID-19 (1)  ·  Cardiovascular Diseases (1)  ·  Cognitive Dysfunction (1)  ·  Disease (1)  ·  Gastrointestinal Neoplasms (1)  ·  Inflammation (1)  ·  Intermittent Claudication (1)  ·  Renal Insufficiency (1)

Broader conditions

Embolism and Thrombosis (13)  ·  Vascular Diseases (13)  ·  Cardiovascular Diseases (12)  ·  Lung Diseases (11)  ·  Respiratory Tract Diseases (11)  ·  Thromboembolism (5)  ·  Thrombosis (5)  ·  Pathological Conditions, Signs and Symptoms (3)  ·  Heart Diseases (2)  ·  Pathologic Processes (2)  ·  Ventricular Dysfunction (2)  ·  Cognition Disorders (1)  ·  Coronaviridae Infections (1)  ·  Coronavirus Infections (1)

Interventions

Enoxaparin (3)  ·  Dalteparin (2)  ·  MAA868 (2)  ·  abelacimab (2)  ·  apixaban (2)  ·  Diclofenac (1)  ·  Heart-Lung Machine (1)  ·  Heparin (1)  ·  Heparin, Low-Molecular-Weight (1)  ·  Magnetic Resonance Spectroscopy (1)  ·  Oxygenators, Membrane (1)  ·  Rivaroxaban (1)  ·  Sodium Chloride (1)  ·  Technetium (1)  ·  Tenecteplase (1)

Sponsors

Anthos Therapeutics, Inc. (2)  ·  Hamilton Health Sciences Corporation (2)  ·  ARCA Biopharma, Inc. (1)  ·  Centre Hospitalier Universitaire de Saint Etienne (1)  ·  Cyclomedica Australia PTY Limited (1)  ·  Ministry of Health, Spain (1)  ·  Rajaie Cardiovascular Medical and Research Center (1)  ·  University Health Network, Toronto (1)  ·  University of Rochester (1)  ·  University of Zurich (1)  ·  Wake Forest University Health Sciences (1)

Countries

Canada (6)  ·  United States (6)  ·  France (3)  ·  Germany (3)  ·  Italy (3)  ·  Spain (3)  ·  Switzerland (3)  ·  Australia (2)  ·  Austria (2)  ·  China (2)  ·  Czechia (2)  ·  Hungary (2)  ·  Ireland (2)  ·  Latvia (2)  ·  Netherlands (2)

Top investigators

Agnes Y Lee, MD (1)  ·  Akash Sharma, MD (1)  ·  Alexander G Turpie, MB (1)  ·  Charles W. Francis, MD (1)  ·  Clive Kearon, MD, PhD (1)  ·  David Jimenez, MD, PhD (1)  ·  David Leung, MD, PhD (1)  ·  Edward M Aten, MD (1)  ·  James Douketis, MD (1)  ·  Jeffrey A Kline, MD (1)  ·  Jeffrey Ginsberg, M.D. (1)  ·  Jeffrey I Weitz, MD (1)  ·  Jeffrey S Ginsberg, MD (1)  ·  Mark A Crowther, MD (1)

Results publications

PMID 25433511, PMID 28139259, PMID 29247809, PMID 32907635, PMID 33337539, PMID 33857326, PMID 35470214, PMID 35779558, PMID 36260302, PMID 37591523

NIH funding

2016 (1), 2023 (1), R01HL095109 (1)